{
  "source_document": "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf",
  "test_cases": [
    {
      "id": "mali_tb_001",
      "query": "How many TB participants were included in the final analysis and how many completed the study at Month-15?",
      "ground_truth_answer": "A total of 155 TB patients were enrolled in the longitudinal cohort study. However, only 30 TB participants who were infected with Mtb complex strains confirmed by phenotypic and genotypic identification methods were included in the final analysis. Of these, 23 (76.6%) completed the study at Month-15",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_002",
      "query": "What was the first-line anti-tuberculosis treatment regimen used in this study?",
      "ground_truth_answer": "The first-line anti-tuberculosis treatment regimen comprised two months of isoniazid (H), rifampin (R), pyrazinamide (Z), and ethambutol (E), followed by four months of rifampin (R) and isoniazid (H), denoted as 2HRZE/4RH",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_003",
      "query": "How many times higher are treated TB patients at risk of experiencing a new TB episode compared to the general population?",
      "ground_truth_answer": "Treated and cured individuals are at least 8 times more likely to experience a new episode of TB disease than the general population",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_004",
      "query": "What were the four time points at which TB patients were sampled in this longitudinal study?",
      "ground_truth_answer": "TB participants had four study visits for clinical investigation and sample collection: before TB treatment initiation (TB_M0), two months (TB_M2), and six months (TB_M6) during anti-tuberculosis therapy, and then nine months after treatment completion (TB_M15)",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_005",
      "query": "How many metabolites were found to be statistically significant across the three TB time points studied?",
      "ground_truth_answer": "Using ANOVA with repeated measures, 470 metabolites were found to be statistically significant across the three groups (TB_M0, TB_M6, and TB_M15) with FDR<0.1",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_006",
      "query": "Explain how the Shannon diversity of gut microbiota changed over the course of TB treatment",
      "ground_truth_answer": "Shannon diversity increased in patients' gut microbiota over time. TB_M0 and TB_M2 were significantly different from healthy controls, while TB_M6 and TB_M15 showed no significant difference from healthy controls according to TukeyHSD ANOVA analysis. This indicates that microbial diversity gradually recovered during and after treatment",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_007",
      "query": "Describe the changes observed in the phyla Firmicutes and Proteobacteria during TB treatment",
      "ground_truth_answer": "At the phylum level, Firmicutes increased significantly with time after treatment, while Proteobacteria decreased significantly. These changes were determined using linear mixed effect models with FDR<0.1",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_008",
      "query": "What role does quinolinate play in TB treatment and how is it related to gut microbiota?",
      "ground_truth_answer": "Quinolinate (quinolinic acid) is a marker for kynurenine in the tryptophan pathway. The study found a negative correlation between the genus Actinosynnema, Megasphaera, and Roseburia relative abundances and the quinolinate metabolite. Antibiotics during TB treatment, mainly pyrazinamide and isoniazid, disturb the metabolic pathways of quinolinic acid, and the kynurenine/tryptophan ratio is a great biomarker for pulmonary tuberculosis",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_009",
      "query": "How does arachidonic acid relate to TB pathogenesis and gut microbiota dysbiosis?",
      "ground_truth_answer": "Arachidonic acid, a polyunsaturated fatty acid, negatively correlates with the abundance of Actinosynnema. This acid is used by Mtb via biosynthesis in infected macrophages, which impairs their inflammatory and antimicrobial activities. Its persistence nine months after TB treatment may explain the higher vulnerability of cured TB patients to new TB episodes",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_010",
      "query": "What changes were observed in the Euryarchaeota phylum during TB treatment?",
      "ground_truth_answer": "Euryarchaeota, one of the two major known archaeal phyla, decreased from the gut microbiota of TB_M0 and at TB_M2 (during isoniazid and rifampicin regimen), then the level increased at TB_M6 before being finally decreased again at TB_M15. This demonstrates that TB treatment affects not only bacteria but also archaea in the gut",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_011",
      "query": "Describe the functional pathway changes observed in TB patients compared to healthy controls",
      "ground_truth_answer": "In TB patients, 75 pathways increased with time and 11 decreased with time using linear mixed effect models (FDR<0.1). Compared with healthy controls, 11 pathways were less abundant at TB_M0 and 212 pathways were more abundant. Among these pathways, four were still less abundant and 15 were still more abundant at TB_M2. None of these pathways were significantly different between TB_M6 and controls, while three became significantly more abundant at TB_M15 again",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_012",
      "query": "Compare the cytokine profiles observed during TB treatment, specifically IL-6, IFN-γ, and IL-17A",
      "ground_truth_answer": "IL-6 and IFN-γ were the most significantly higher levels of cytokines, which play an important role in the acute phase response against Mtb. During TB treatment, their levels decreased before total bacterial clearance, predicting positive TB treatment outcomes. In contrast, IL-17A, known to have a strong link with the gut, was highly expressed during the treatment period, and the trend was maintained a long time after completion at TB-M15",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "hard",
      "category": "comparison"
    },
    {
      "id": "mali_tb_013",
      "query": "Explain the relationship between the modern Euro-American lineage 4 Mtb strains and treatment response compared to other lineages",
      "ground_truth_answer": "A total of 19/30 (63.33%) of the TB patients were infected with the modern Euro-American lineage 4, which showed a high amount of persistence of sputum smear positivity at month-2 of TB treatment at 10/13 (76.92%). The other circulating lineages in Mali (lineage 1, lineage 2, and lineage 3) were more responsive to the anti-TB drugs, with 8/11 (72.72%) clearing at this time point, indicating that strain lineage affects treatment response",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "hard",
      "category": "comparison"
    },
    {
      "id": "mali_tb_014",
      "query": "Compare the metabolomic profiles at different time points using PCA and HCA analyses",
      "ground_truth_answer": "Principal Components Analysis (PCA) plots showed that TB_M0 is distinct and separated from TB_M6 and TB_M15, indicating that the treatment effects on metabolites were maintained at least nine months after treatment completion. The overlap between TB_M6 and TB_M15 suggests their metabolic profiles are similar and different from the pre-treatment/infection stage. Using Hierarchical Clustering Analysis (HCA), five groupings of 15 subjects' samples were found, with a cluster of nine pre-treatment samples suggesting good similarities among pre-treatment samples",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "hard",
      "category": "comparison"
    },
    {
      "id": "mali_tb_015",
      "query": "Describe the comprehensive metabolic pathway correlations found with both taxa abundance and metabolites in TB patients",
      "ground_truth_answer": "The study found significant correlations between genus/pathway and metabolite abundance. Taxa correlated with metabolite production belong to bacteria phyla Proteobacteria, Actinobacteria, Firmicutes, and Euryarchaeota from archaea. Fatty acids like quinolinate and arachidonate levels decreased with increased taxa. Negative correlation was found between quinolinate and both Guanosine and methylerythritol phosphate pathway I. Ornithine negatively correlated with glycolysis, tricarboxylic acid cycle, and glyoxylate bypass. Citrulline and kynurenate positively correlated with histidine, purine, and pyrimidine biosynthesis, aromatic amino acid biosynthesis, and starch degradation V pathway",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "hard",
      "category": "mechanism"
    }
  ],
  
  "mcq_questions": [
    {
      "id": "mali_tb_mcq_001",
      "question": "What sequencing platform was used for shotgun metagenomics of the gut microbiome in this study?",
      "options": [
        "A) Illumina MiSeq",
        "B) Illumina HiSeq 4000",
        "C) PacBio Sequel",
        "D) Oxford Nanopore"
      ],
      "correct_answer": "B",
      "explanation": "DNA from stool samples was sequenced at the University of Illinois at Chicago (UIC) Research Genome Core Laboratory employing Illumina HiSeq 4000 using 150 bp paired-end reads",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_002",
      "question": "How many deaths from TB were reported globally in 2022 according to the paper?",
      "options": [
        "A) 500,000 deaths among HIV-negative and 50,000 among HIV-positive",
        "B) 1.13 million deaths among HIV-negative and 167,000 among HIV-positive",
        "C) 2 million deaths among HIV-negative and 300,000 among HIV-positive",
        "D) 780,000 deaths among HIV-negative and 100,000 among HIV-positive"
      ],
      "correct_answer": "B",
      "explanation": "Tuberculosis remains ranked as one of the leading causes of death from a single pathogen, with 1.13 million deaths among HIV-negative patients and 167,000 deaths among HIV-positive patients reported only in 2022",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_003",
      "question": "What was the mean age of TB patients in this study?",
      "options": [
        "A) 25.8 years",
        "B) 28.5 years",
        "C) 32.5 years",
        "D) 37.2 years"
      ],
      "correct_answer": "C",
      "explanation": "The mean age for TB patients was 32.5 years (SD: 11.8), which was significantly different from healthy controls who had a mean age of 25.8 years (SD: 5.7) with p=0.012",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "easy",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_004",
      "question": "How many taxa across taxonomic levels from phylum to species increased with time in TB patients, and how many decreased?",
      "options": [
        "A) 200 increased, 50 decreased",
        "B) 411 increased, 9 decreased",
        "C) 815 increased, 2 decreased",
        "D) 75 increased, 11 decreased"
      ],
      "correct_answer": "B",
      "explanation": "In patients, 411 taxa across taxonomic levels from phylum to species increased with time, and 9 decreased with time according to linear mixed effect models with FDR<0.1",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_005",
      "question": "How many metabolites were significantly different between TB_M0 and TB_M6?",
      "options": [
        "A) 103 metabolites",
        "B) 212 metabolites",
        "C) 361 metabolites",
        "D) 428 metabolites"
      ],
      "correct_answer": "C",
      "explanation": "By comparing each pair of groups with ANOVA contrast, 361 metabolites were significantly different between TB_M0 and TB_M6, 103 metabolites were significantly different between TB_M6 and TB_M15, and 428 metabolites were significantly different between TB_M0 and TB_M15",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_006",
      "question": "Which of the following best describes the study's findings about beta-diversity?",
      "options": [
        "A) Beta-diversity remained constant throughout treatment",
        "B) Beta-diversity of TB_M0 and TB_M6 were significantly higher than healthy controls and TB_M15, while TB_M15 was similar to healthy controls",
        "C) Beta-diversity increased progressively from TB_M0 to TB_M15",
        "D) Beta-diversity was not significantly different between any groups"
      ],
      "correct_answer": "B",
      "explanation": "The beta-diversity of TB_M0 and TB_M6 were significantly higher than that of healthy controls and TB_M15, while the beta-diversity of TB_M15 is similar to that of healthy controls, indicating recovery toward normal diversity levels",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_mcq_007",
      "question": "What were the seven cytokines measured in this study using the Human Th1/Th2/Th17 kit?",
      "options": [
        "A) IL-1, IL-2, IL-4, IL-6, IL-8, TNF, IFN-γ",
        "B) IL-2, IL-4, IL-6, IL-10, TNF, IFN-γ, IL-17A",
        "C) IL-2, IL-4, IL-6, IL-8, IL-10, TNF, IFN-γ",
        "D) IL-1, IL-4, IL-6, IL-10, IL-12, TNF, IFN-γ"
      ],
      "correct_answer": "B",
      "explanation": "The BD CBA assessed Interleukin-2 (IL-2), IL-4, IL-6, IL-10, TNF, IFN-γ, and IL-17A levels in plasma samples using the Human Th1/Th2/Th17 kit",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_008",
      "question": "What was the average number of sequencing reads per sample obtained in this study?",
      "options": [
        "A) 5,000,000 reads",
        "B) 10,000,000 reads",
        "C) 20,311,846 reads",
        "D) 31,329,790 reads"
      ],
      "correct_answer": "C",
      "explanation": "The sequencing reads ranged from 496,978 to 31,329,790 across 122 samples, with an average of 20,311,846 reads per sample",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "medium",
      "category": "factual"
    },
    {
      "id": "mali_tb_mcq_009",
      "question": "According to the PERMANOVA test results, which time points showed significant differences from healthy controls in terms of gut microbiota composition?",
      "options": [
        "A) Only TB_M0 was significantly different",
        "B) TB_M0 and TB_M2 were significantly different, while TB_M6 and TB_M15 were not",
        "C) All time points (TB_M0, TB_M2, TB_M6, TB_M15) were significantly different from healthy controls",
        "D) None of the time points were significantly different"
      ],
      "correct_answer": "C",
      "explanation": "The gut microbiota of TB_M0 and TB_M2 were distinct from healthy controls. While TB_M6 and TB_M15 microbiota became more similar to healthy controls, they were still significantly different (PERMANOVA test: TB_M6 vs Healthy: R²=0.065, P=0.002; TB_M15 vs Healthy: R²=0.087, P=0.001)",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "hard",
      "category": "mechanism"
    },
    {
      "id": "mali_tb_mcq_010",
      "question": "What is the significance of the study's findings regarding the persistence of gut microbiota alterations nine months after TB treatment completion?",
      "options": [
        "A) It suggests complete recovery of the microbiome within 6 months",
        "B) It indicates that dysbiosis persists long after treatment and may contribute to increased vulnerability to recurrent TB",
        "C) It shows that the microbiome returns to pre-infection state immediately after treatment",
        "D) It demonstrates no relationship between microbiome changes and TB recurrence risk"
      ],
      "correct_answer": "B",
      "explanation": "The study found that altered microbial community in the gut environment persisted for at least nine months after treatment completion. This gut microbiome dysbiosis induced by anti-tuberculosis treatment may contribute to the risk of recurrent TB, as it causes long-lasting damage that impacts the homeostatic role of the microbiome in inflammation and other metabolic functions essential for resistance against Mtb. This helps explain why treated TB patients are at least 8 times more likely to develop a new TB episode than the general population",
      "expected_documents": [
        "22-Metabolic_and_immune_consequences_of_antibiotic_related_microbiome_alterations_during_first-line_tuberculosis_treatment_in_Bamako__Mali.pdf"
      ],
      "difficulty": "hard",
      "category": "mechanism"
    }
  ]
}